StockData
Silo Pharma, Inc. logo

Silo Pharma, Inc. (SILO) stock

SILONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 3/30
$1.84−0.07 (-3.66%)

Close on Nov 13, 2026Market cap $2.92MP/E –Yield –

Silo Pharma r&d expenses

Research and development expenses are spending on new products and technology.

Silo Pharma's R&D Expenses for the twelve months ending Sep 30, 2026 was $2.18M, down 25.7% year over year. For fiscal 2025 it was $2.16M, down 8.8% from the year before. The highest annual figure on record is $2.37M in fiscal 2024.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$2.16M-8.8%
FY2024Dec 31, 2024$2.37M+180.2%
FY2023Dec 31, 2023$845.09K-34.3%
FY2022Dec 31, 2022$1.29M+85.4%
FY2021Dec 31, 2021$693.91K+2543.5%
FY2020Dec 31, 2020$26.25K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$559.09K+2.8%
Q2 FY2026Jun 30, 2026$298.42K-58.4%
Q1 FY2026Mar 31, 2026$1.01M+70.6%
Q4 FY2025Dec 31, 2025$306.01K-71.6%
Q3 FY2025Sep 30, 2025$543.62K+5.0%
Q2 FY2025Jun 30, 2025$717.25K+112.9%
Q1 FY2025Mar 31, 2025$593.96K+78.0%
Q4 FY2024Dec 31, 2024$1.08M+69.5%
Q3 FY2024Sep 30, 2024$517.55K+37.7%
Q4 FY2023Dec 31, 2023$336.97K+218.9%
Q1 FY2023Jun 30, 2023$333.63K+95.9%
Q4 FY2022Dec 31, 2022$634.68K+33.4%
Q3 FY2022Sep 30, 2022$375.80K+432.9%
Q2 FY2022Jun 30, 2022$105.68K+6.9%
Q1 FY2022Mar 31, 2022$170.28K+250.4%
Q4 FY2021Dec 31, 2021$475.95K–
Q3 FY2021Sep 30, 2021$70.51K–
Q2 FY2021Jun 30, 2021$98.85K–
Q1 FY2021Mar 31, 2021$48.60K–

More Silo Pharma figures

See a number that looks wrong?